Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 8, 2009 - Issue 4
Submit an article Journal homepage
518
Views
20
CrossRef citations to date
0
Altmetric
Drug Safety Evaluations

Update on the safety of linezolid

Eugenios I Metaxas Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Greece +30 694 611 0000; +30 210 683 9605; [email protected]
, MD &
Matthew E Falagas Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Greece +30 694 611 0000; +30 210 683 9605; [email protected]; Tufts University School of Medicine, Department of Medicine, Boston, Massachusetts, USA
, MD MSc DSc
Pages 485-491 | Published online: 21 Jun 2009

Bibliography

  • Livermore DM. Linezolid in vitro: mechanism and antibacterial spectrum. J Antimicrob Chemother 2003;51(Suppl S2):ii9-16
  • Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003;138:135-42
  • Zhanel GG, Schroeder C, Vercaigne L, et al. A critical review of oxazolidinones: an alternative or replacement for glycopeptides and streptogramins? Can J Infect Dis 2001;12(6)
  • Patel U, Yan PY, Hobbs FW, et al. Oxazolidinones mechanism of action: inhibition of the first peptide bond formation. J Biol Chem 2001;276(40):37199-205
  • Swaney SM, Aokiand H, Ganozaand MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998;42:3251-5
  • Zurenko GE, Todd WM, Hafkin B, et al. Development of linezolid resistant Enterococcus faecium in two compassionate use program patients treated with linezolid. In 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco; 1999
  • NY Pharmacia & Upjohn, Division of Pfizer, Inc. Zyvox package insert, May 2008. Available from: http://www.fda.gov/medwatch/safety/2008/Jun_PI/Zyvox_PI.pdf. [Last accessed on 9 May 2009]
  • Johnson AP, Tysall L, Stockdale MW, et al. Emerging linezolid resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit. Eur J Clin Microbiol Infect Dis 2002;21:751-4
  • Gonzales RD, Schreckenberger PC, Graham MB, et al. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001;357:1179
  • Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001;358(9277):207-8
  • Wilson P, Andrews JA, Charlesworth R, et al. Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 2003;51:186-8
  • Potoski BA, Adams J, Clarke L, et al. Epidemiological profile of linezolid-resistant coagulase-negative staphylococci. Clin Infect Dis 2006;43(2):165-71
  • MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003;51(Suppl S2):ii17-25
  • Ament PW, Jamshed N, Horne JP. Linezolid: its role in the treatment of Gram-positive, drug-resistant bacterial infections. Am Fam Physician 2002;65(4):663
  • French G. Safety and tolerability of linezolid. J Antimicrob Chemother 2003;51(Suppl S2):ii45-53
  • FDA, Information for Healthcare Professionals. Available from: http://www.fda.gov/cder/drug/InfoSheets/HCP/linezolidHCP.pdf, June 2007. [Last accessed on 9 May 2009]
  • Falagas ME, Manta KG, Ntziora F, Vardakas KZ. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother 2006;58(2):273-80
  • Hill EE, Herijgers P, Herregods MC, Peetermans WE. Infective endocarditis treated with linezolid: case report and literature review. Eur J Clin Microbiol Infect Dis 2006;25:202-4
  • Sabbatani S, Manfredi R, Frank G. Linezolid in the treatment of central nervous system infections resistant to recommended antimicrobial compounds. Infez Med 2005;13:112-19
  • Falagas ME, Siempos II, Papagelopoulos PJ, Vardakas KZ. Linezolid for the treatment of adults with bone and joint infections. Int J Antimicrob Agents 2007;29(3):233-9
  • Barberan J. Management of infections of osteoarticular prosthesis. Clin Microbiol Infect 2006;12(Suppl 3):93-101
  • Harwood PJ, Giannoudis PV. The safety and efficacy of linezolid in orthopedic practice for the treatment of infection due to antibiotic-resistant organisms. Expert Opin Drug Saf 2004;3(5):405-14
  • Manfredi R. Update on the appropriate use of linezolid in clinical practice. Ther Clin Risk Manag 2006;2(4):455-64
  • Antal EJ, Hendershot PE, Batts DH, et al. Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine. J Clin Pharmacol 2001;41(5):552-62
  • Cantarini MV, Painter CJ, Gilmore EM, et al. Effect of oral linezolid on the pressor response to intravenous tyramine. Br J Clin Pharmacol 2004;58(5):470-5
  • FDA. Detailed View: safety labeling changes Approved By FDA Center for Drug Evaluation and Research (CDER). Available from: http://www.fda.gov/medwatch/safety/2008/jun08.htm#Zyvox June 2008. [Last accessed on 9 May 2009]
  • Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis 2006;42:1578-83
  • Black K, Shea C, Dursun S, Kutcher S. Selective serotonin reuptake syndrome: proposed diagnostic criteria. Psychiatry Neurosci 2000;25:255-61
  • Rubinstein E, Cammarata SK, Oliphant TH, Wunderink RG. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001;32:402-12
  • Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. Clin Infect Dis 2002;34(11):1481-90
  • San Pedro GS, Cammarata SK, Oliphant TH, et al. Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. Scand J Infect Dis 2002;10:720-8
  • Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000;44(12):3408-13
  • Rubinstein E, Isturiz R, Standiford HC, et al. Worldwide clinical safety and tolerability with linezolid: comparator-controlled phase III experience. Antimicrob Agents Chemother 2003;47(6):1824-31
  • Cammarata SK, Le V, Oliphant TH, et al. Incidence of clostridium difficile-related complications during clinical trials of linezolid, an oxazolidinone. Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000; Abstract 947:411
  • Bernstein WB, Trotta RF, Rector JT, et al. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother 2003;37:517-20
  • Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate use program. Clin Infect Dis 2003;36:159-68
  • Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002;46:2723-6
  • Soriano A, Gomez J, Gomez L, et al. Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections. Eur J Clin Microbiol Infect Dis 2007;26(5):353-6
  • Plachouras D, Giannitsioti E, Athanassia S, et al. No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment. Clin Infect Dis 2006;43(9):e89-91
  • Nasraway SA, Shorr AF, Kuter DJ, et al. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis 2003;37(12):1609-16
  • Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or β-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008;8(1):53-66
  • Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 2006;42(1):66-72
  • Lin YH, Wu VC, Tsai IJ, et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents 2006;28(4):345-51
  • Spellberg B, Yoo T, Bayer AS. Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J Antimicrob Chemother 2004;54:832-5
  • Youssef S, Hachem R, Chemaly RF, et al. The role of vitamin B6 in the prevention of haematological toxic effects of linezolid in patients with cancer. J Antimicrob Chemother 2008;61(2):421-4
  • Soriano A, Ortega M, Garcia S, et al. Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid. Antimicrob Agents Chemother 2007;51(7):2559-63
  • Thai XC, Bruno-Murtha LA. Bell's palsy associated with linezolid therapy: case report and review of neuropathic adverse events. Pharmacotherapy 2006;26(8):183-9
  • Javaheri M, Khurana RN, O'Hearn TM, et al. Linezolid-induced optic neuropathy: a mitochondrial disorder? Br J Ophthalmol 2007;91:111-5
  • Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004;4:528-31
  • Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 2007;27(8):1189-97
  • Pea F, Scudeller L, Lugano M, et al. Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient. Clin Infect Dis 2006;42(3):434-5
  • Wiener M, Guo Y, Patel G, Fries BC. Lactic acidosis after treatment with linezolid. Infection 2007;35(4):278-81
  • Kopterides P, Papadomichelakis E, Armaganidis A. Linezolid use associated with lactic acidosis. Scand J Infect Dis 2005;37:153-4
  • Soriano A, Miro O, Mensa J. Mitochondrial toxicity associated with linezolid. N Engl J Med 2005;353(21):2305-6
  • De Vriese AS, Coster RV, Smet J, et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 2006;42(8):1111-7
  • Palenzuela L, Hahn NM, Nelson RP Jr, et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis 2005;40(12):e113-6
  • Carson J, Cerda J, Chae JH, et al. Severe lactic acidosis associated with linezolid use in a patient with the mitochondrial DNA A2706G polymorphism. Pharmacotherapy 2007;27(5):771-4
  • Esposito L, Kamar N, Guilbeau-Frugier C, et al. Linezolid-induced interstitial nephritis in a kidney-transplant patient. Clin Nephrol 2007;68(5):327-9
  • Tsuji Y, Hiraki Y, Mizoguchi A, et al. Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure. J Infect Chemother 2008;14(2):156-60
  • Kaplan SL, Patterson L, Edwards KM, et al. Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Pediatric Infect Dis J 2001;20:488-94
  • Fleishaker DL, Anderson DC, Bruss JB, et al. Clinical efficacy of linezolid (LZD)in the treatment of otitis media. Clin Infect Dis 2000;31:224
  • Kaplan SL, Deville JG, Yogev R, et al. Linezolid vs vancomycin in the treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J 2003;22(8):677-86
  • Falagas ME, Vardakas KZ. Benefit-risk assessment of linezolid for serious gram-positive bacterial infections. Drug Saf 2008;31(9):753-68
  • Ntziora F, Falagas ME. Linezolid for the treatment of patients with mycobacterial infections a systematic review. Int J Tuberc Lung Dis 2007;11(6):606-11
  • Karchmer AW. Nosocomial bloodstream infections: organisms, risk factors, and implications. Clin Infect Dis 2000;31(Suppl 4):S139-43
  • Barrett JF. Linezolid Pharmacia Corp. Curr Opin Investig Drugs 2000;1(2):181-7
  • Top 200 drugs for 2007 by sales. Available from: http://www.drugs.com/top200.html. [Last accessed on 9 May 2009]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.